Losartan Potassium Tablet
Product Images NDC 50090-3403

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-3403). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Deb2d34c 8675 422d 944e E8026c82f6c2 01)

Chemical structure of losartan potassium, showing the molecular arrangement including a chloro-substituted imidazole ring, biphenyl group, and potassium ion.*

FDA Label Image

Image (Deb2d34c 8675 422d 944e E8026c82f6c2 02)

A line chart comparing the percentage of patients with primary endpoint events over time (in study months) for Atenolol and Losartan treatments. The x-axis represents study months from 0 to 66, and the y-axis shows percentage of patients from 0 to 16%. Atenolol is shown with a dotted line, Losartan with a solid line, illustrating adjusted risk reduction of 13% with p=0.021.*

FDA Label Image

Image (Deb2d34c 8675 422d 944e E8026c82f6c2 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Atenolol (dotted line) and Losartan (solid line). The graph includes an adjusted risk reduction of 25% for Losartan with a p-value of 0.001, indicating statistical analysis of stroke outcomes over time.*

FDA Label Image

Image (Deb2d34c 8675 422d 944e E8026c82f6c2 04)

A comparative forest plot chart showing primary composite and stroke (fatal/non-fatal) event rates and hazard ratios with 95% confidence intervals for Losartan Potassium versus Atenolol in different patient subgroups. The chart includes overall results and breakdowns by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD), illustrating outcomes favoring either Losartan or Atenolol.*

FDA Label Image

Image (Deb2d34c 8675 422d 944e E8026c82f6c2 05)

A line chart showing the percentage of patients with an event over 48 months comparing Losartan and Placebo. The x-axis represents months, and the y-axis represents the percentage of patients with an event. The chart indicates a 16.1% risk reduction with Losartan compared to Placebo, with a p-value of 0.022.*

FDA Label Image

Label Image (Lbl500903403)

Losartan Potassium 100 mg oral tablet packaging label from A-S Medication Solutions. The label includes NDC 50090-3403-0, product number 6297-0, and lot information. It instructs to store at 77 degrees Fahrenheit and protect from light. The package contains 90 tablets with dosage instructions printed separately.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.